Pseudouridimycin
Product Code: AG-CN2-0316
Product Group: Natural Products and Extracts
Supplier: AdipoGen Life Sciences
| Code | Size | Price |
|---|
| AG-CN2-0316-M001 | 1 mg | £140.00 |
Quantity:
| AG-CN2-0316-M005 | 5 mg | £530.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
AMBIENT
Storage:
-20°C
Documents
Further Information
Alternate Names/Synonyms:
PUM
Appearance:
Off-white to yellow powder.
CAS:
1566586-52-4
EClass:
32160000
Form (Short):
liquid
Handling Advice:
Keep cool and dry.Protect from light.Protect from light when in solution.
InChi:
InChI=1S/C17H26N8O9/c18-9(26)2-1-7(25(33)10(27)5-22-16(19)20)15(31)21-4-8-11(28)12(29)13(34-8)6-3-23-17(32)24-14(6)30/h3,7-8,11-13,28-29,33H,1-2,4-5H2,(H2,18,26)(H,21,31)(H4,19,20,22)(H2,23,24,30,32)/t7-,8+,11+,12+,13-/m0/s1
InChiKey:
XDEYHXABZOKKDZ-YFKLLHAASA-N
Long Description:
Chemical. CAS: 1566586-52-4. Formula: C17H26N8O9. MW: 486.4. Isolated from Streptomyces sp. Peptidyl nucleoside antibiotic. Selective nucleoside-analog inhibitor of bacterial RNA polymerase (RNAP). Inhibits RNAP through a distinctive binding site on RNAP (the NTP addition site) and mechanism (competition with UTP for occupancy of the NTP addition site) than Rifampin. Targets bacterial RNAP in Gram-positive and Gram-negative organisms, including antibiotic-resistant isolates and shows extremely low frequency of resistance selection. Potently inhibits bacterial RNAP in vitro, inhibits bacterial growth in culture, and has shown in vivo efficacy in animal models of infection.
MDL:
MFCD32215322
Molecular Formula:
C17H26N8O9
Molecular Weight:
486.4
Package Type:
Vial
Product Description:
Peptidyl nucleoside antibiotic. Selective nucleoside-analog inhibitor of bacterial RNA polymerase (RNAP). Inhibits RNAP through a distinctive binding site on RNAP (the NTP addition site) and mechanism (competition with UTP for occupancy of the NTP addition site) compared to rifampin. Targets bacterial RNAP in Gram-positive and Gram-negative organisms, including antibiotic-resistant isolates and shows extremely low frequency of resistance selection. Potently inhibits bacterial RNAP in vitro, inhibits bacterial growth in culture and has shown in vivo efficacy in animal models of infection.
Purity:
>85% (HPLC)
SMILES:
O[C@H]1[C@H](C(C(N2)=O)=CNC2=O)O[C@H](CNC([C@H](CCC(N)=O)N(O)C(CNC(N)=N)=O)=O)[C@H]1O
Solubility Chemicals:
Soluble in DMSO or water.
Source / Host:
Isolated from Streptomyces sp.
Transportation:
Non-hazardous
UNSPSC Category:
Natural Products/Extracts
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
Antibacterial Nucleoside-Analog Inhibitor of Bacterial RNA Polymerase: S.I. Maffioli, et al.; Cell 169, 1240 (2017) | Pseudouridimycin: The First Nucleoside Analogue That Selectively Inhibits Bacterial RNA Polymerase: M.F. Chellat & R. Riedl; Angew. Chem. Int. Ed. Engl. 56, 13184 (2017) | Novel RNA polymerase inhibitor found in soil extracts provides hope for future antibacterial drugs: R.H. Ebright; Future Med. Chem. 9, 1857 (2017)
Related Products
| Product Name | Product Code | Supplier | Rifamycin AF-API | AG-CN2-0325 | AdipoGen Life Sciences | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rifamycin AF-EPTAPI | AG-CN2-0326 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Rifamycin AF-DA | AG-CN2-0328 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Rifamycin AG | AG-CN2-0329 | AdipoGen Life Sciences | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||